MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.healun.2023.06.015

Медицинская библиотека · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023

Expanding use of the HeartMate 3 ventricular assist device in pediatric and adult patients within the Advanced Cardiac Therapies Improving Outcomes Network (ACTION).

O'Connor Matthew J, Shezad Muhammad, Ahmed Humera, Amdani Shahnawaz, Auerbach Scott R, Bearl David W, Butto Arene, Byrnes Jonathan W, Conway Jennifer, Dykes John C, Glass Lauren, Lantz Jodie, Law Sabrina, Mongé Michael C, Morales David L S, Parent John J, Peng David M, Ploutz Michelle S, Puri Kriti, Shugh Svetlana, Shwaish Natalie S, VanderPluym Christina J, Wilkens Sarah, Wright Lydia, Zinn Matthew D, Lorts Angela

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

We report current outcomes in patients supported with the HeartMate 3 (HM3) ventricular assist device in a multicenter learning network.

METHODS

The Advanced Cardiac Therapies Improving Outcomes Network database was queried for HM3 implants between 12/2017 and 5/2022. Clinical characteristics, postimplant course, and adverse events were collected. Patients were stratified according to body surface area (BSA) (<1.4 m2, 1.4-1.8 m2, and >1.8 m2) at device implantation.

RESULTS

During the study period, 170 patients were implanted with the HM3 at participating network centers, with median age 15.3years; 27.1% were female. Median BSA was 1.68 m2; the smallest patient was 0.73 m2 (17.7 kg). Most (71.8%) had a diagnosis of dilated cardiomyopathy. With a median support time of 102.5days, 61.2% underwent transplantation, 22.9% remained supported on device, 7.6% died, and 2.4% underwent device explantation for recovery; the remainder had transferred to another institution or transitioned to a different device type. The most common adverse events included major bleeding (20.8%) and driveline infection (12.9%); ischemic and hemorrhagic stroke were encountered in 6.5% and 1.2% of patients, respectively. Patients with BSA <1.4 m2 had a higher incidence of infection, renal dysfunction, and ischemic stroke.

CONCLUSIONS

In this updated cohort of predominantly pediatric patients supported with the HM3 ventricular assist device, outcomes are excellent with <8% mortality on device. Device-related adverse events including stroke, infection, and renal dysfunction were more commonly seen in smaller patients, highlighting opportunities for improvements in care.

Для цитирования: O'Connor Matthew J, Shezad Muhammad, Ahmed Humera, Amdani Shahnawaz, Auerbach Scott R, Bearl David W, Butto Arene, Byrnes Jonathan W, Conway Jennifer, Dykes John C, Glass Lauren, Lantz Jodie, Law Sabrina, Mongé Michael C, Morales David L S, Parent John J, Peng David M, Ploutz Michelle S, Puri Kriti, Shugh Svetlana, Shwaish Natalie S, VanderPluym Christina J, Wilkens Sarah, Wright Lydia, Zinn Matthew D, Lorts Angela. Expanding use of the HeartMate 3 ventricular assist device in pediatric and adult patients within the Advanced Cardiac Therapies Improving Outcomes Network (ACTION).. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2023. DOI: 10.1016/j.healun.2023.06.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.